Trial reportRetina (Philadelphia, Pa.)2019
ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: An Independent Analysis of Protocol i Study Data.
Trial report in Retina (Philadelphia, Pa.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.American journal of ophthalmology · 2021Trial
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema.Ophthalmology and therapy · 2026Article
- First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria.Journal of clinical medicine · 2026Article
- Inflammatory Biomarkers in Diabetic Macular Edema.Journal of clinical medicine · 2026Review
- Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review.Ophthalmology and therapy · 2026Review
- Dexamethasone implant vs. anti-VEGF for diabetic macular edema with epiretinal membrane: short-term outcomes.International journal of retina and vitreous · 2026Article
- Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study.The British journal of ophthalmology · 2025Article
- Beyond the First Year of Intravitreal Faricimab for Diabetic Macular Oedema: A Single-Centre Experience.Cureus · 2025Article
- Article
- Retinal Thickness Analysis Using Optical Coherence Tomography: Diagnostic and Monitoring Applications in Retinal Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- Correlation of limited-early-response status with 12-month CST, BVA, and machine learning-quantified retinal fluid in diabetic macular oedema in routine clinical practice.Eye (London, England) · 2024Article
- Differences between young and elderly polypoidal choroidal vasculopathy patients with and without pachychoroid phenotypes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Machine learning and optical coherence tomography-derived radiomics analysis to predict persistent diabetic macular edema in patients undergoing anti-VEGF intravitreal therapy.Journal of translational medicine · 2024Article
- The effect of glycosylated hemoglobin levels on the response to intravitreal dexamethasone implant for treating diabetic macular edema.Scientific reports · 2024Article
- Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion.International journal of ophthalmology · 2024Article
- Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?Arquivos brasileiros de oftalmologia · 2024Article
- Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema.Eye (London, England) · 2024Review
- Article
- Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.BMJ open ophthalmology · 2023Observational
- The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Descriptive Review.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis post hoc analysis explores the relationship between early retinal anatomical response and long-term anatomical and visual outcomes with ranibizumab in center-involved diabetic macular edema.
methodsEyes randomized to the ranibizumab plus prompt laser and ranibizumab plus deferred laser treatment arms in the Protocol I study were categorized according to their proportional reduction (<20 vs. ≥20%) in central retinal thickness (CRT) after 12 weeks. Adjusted and unadjusted analyses assessed the association between early (Week 12) anatomical response and long-term (Weeks 52 and 156) anatomical and best-corrected visual acuity outcomes.
resultsOf 335 study eyes, 118 showed limited (<20%) and 217 showed strong (≥20%) CRT reduction at Week 12. In unadjusted and adjusted analyses, limited early CRT response was negatively and significantly associated with strong CRT response at Weeks 52 and 156. Sensitivity analyses indicated that this association was robust and unrelated to any "floor effect." In unadjusted analyses, a strong early CRT response was associated with greater long-term improvement in best-corrected visual acuity; after controlling for confounders, the association lost statistical significance.
conclusionEarly CRT response to ranibizumab is a significant prognostic indicator of medium- to long-term anatomical outcome in center-involved diabetic macular edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.